Omnitrope
Prader-Willi Syndrome
University Hospital, ToulousePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Prader-Willi Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Genotropin Corporacion Parc Tauli | Phase 4 | BBB |
Oxytocin University Hospital, Toulouse | Phase 2/3 | BBB |
Dccr Soleno Therapeutics, Inc. | Phase 3 | BB |
Guanfacine Maimonides Medical Center | Phase 4 | BB |
Tirzepatide Grace Kim | Phase 4 | BB |
View all 33 →
Same molecule, other indications
Omnitrope is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →